Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1094482 | 0.95 | SCN9A (0.45) | SCN9ASLC22A12 | |
| SCHEMBL1743705 | 0.88 | SCN9A (0.47) | SCN9ASLC22A12 | |
| SCHEMBL9923646 | 0.86 | SCN9A (0.44) | SCN9A | |
| SCHEMBL1094597 | 0.81 | SCN9A (0.44) | SCN9A | |
| SCHEMBL9923651 | 0.81 | SCN9A (0.44) | SCN9ASLC22A12 | |
| SCHEMBL3478328 | 0.80 | SCN9A (0.42) | SCN9ASLC22A12 | |
| SCHEMBL9924650 | 0.80 | SCN9A (0.38) | SCN9A | |
| SCHEMBL19398409 | 0.77 | SCN9A (0.42) | SCN9A | |
| SCHEMBL9923641 | 0.75 | SCN9A (0.42) | SCN9ASLC22A12 | |
| SCHEMBL1095406 | 0.75 | SCN9A (0.43) | SCN9ASLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8907101-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2014-12-09 | — | — | US | disclosed |
| US-8541588-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2013-09-24 | — | — | US | disclosed |
| US-20120149679-A1 | Sulfonamide Derivatives | ICAGEN, INC. | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149679-A1 | Sulfonamide Derivatives | SULT2A1, SULT1A1, TPST2 | SCN9A 73/4885SLC22A12 999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.